Department of Chemistry, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.
J Org Chem. 2022 Apr 1;87(7):4813-4817. doi: 10.1021/acs.joc.2c00083. Epub 2022 Mar 23.
A concise total synthesis of rucaparib, an FDA-approved drug for ovarian and prostate cancers, is reported. The Heck reaction of the commercially available aryl iodide with acrylonitrile provided the desired ()-2-aminocinnamonitrile derivative. A subsequent imino-Stetter reaction of the aldimine derived from 2-aminocinnamonitrile and aldehyde furnished indole-3-acetonitrile bearing the desired substituents at appropriate positions. The construction of the final azepinone scaffold via reduction of the nitrile group followed by seven-membered lactamization afforded rucaparib. Notably, the synthesis of rucaparib is achieved using commercially available starting materials in only three separation operations with 54% overall yield.
报道了一种 FDA 批准用于卵巢癌和前列腺癌的药物鲁卡帕尼的简洁全合成。通过商业可得的芳基碘化物与丙烯腈的 Heck 反应得到所需的()-2-氨基肉桂腈衍生物。随后,由 2-氨基肉桂腈和醛衍生的亚胺-Stetter 反应在适当位置为吲哚-3-乙腈提供了所需的取代基。通过腈基的还原以及随后的七元内酰胺化构建最终的氮杂环庚酮骨架,得到鲁卡帕尼。值得注意的是,鲁卡帕尼的合成仅使用三步分离操作,使用商业可得的起始原料,总收率为 54%。